U.S. markets open in 3 hours 15 minutes
  • S&P Futures

    3,656.50
    -4.00 (-0.11%)
     
  • Dow Futures

    29,728.00
    -76.00 (-0.25%)
     
  • Nasdaq Futures

    12,443.75
    -8.50 (-0.07%)
     
  • Russell 2000 Futures

    1,831.00
    -4.50 (-0.25%)
     
  • Crude Oil

    44.51
    -0.04 (-0.09%)
     
  • Gold

    1,832.10
    +13.20 (+0.73%)
     
  • Silver

    24.31
    +0.22 (+0.91%)
     
  • EUR/USD

    1.2054
    -0.0025 (-0.20%)
     
  • 10-Yr Bond

    0.9340
    0.0000 (0.00%)
     
  • Vix

    20.84
    +0.27 (+1.31%)
     
  • GBP/USD

    1.3356
    -0.0067 (-0.50%)
     
  • USD/JPY

    104.6900
    +0.3740 (+0.36%)
     
  • BTC-USD

    19,076.73
    -95.01 (-0.50%)
     
  • CMC Crypto 200

    374.32
    -5.54 (-1.46%)
     
  • FTSE 100

    6,399.09
    +14.36 (+0.22%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Why Collegium (COLL) Could Be an Impressive Growth Stock

Zacks Equity Research
·2 min read

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Collegium Pharmaceutical, Inc. COLL. This firm, which is in the Medical - Drugs industry, saw EPS growth of 20.9% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 484.6%. Furthermore, the long-term growth rate is currently an impressive 169.2%, suggesting pretty good prospects for the long haul.

Collegium Pharmaceutical, Inc. Price and Consensus

Collegium Pharmaceutical, Inc. Price and Consensus
Collegium Pharmaceutical, Inc. Price and Consensus

Collegium Pharmaceutical, Inc. price-consensus-chart | Collegium Pharmaceutical, Inc. Quote


And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 52.3%. Thanks to this rise in earnings estimates, COLL has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider COLL. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for COLL as well.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Collegium Pharmaceutical, Inc. (COLL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research